论文部分内容阅读
目的:讨论肿瘤并发贫血的临床治疗方案。方法:从2009年1月-2014年1月和县人民医院化疗的肿瘤患者中选取120例作为研究对象,排除白血病患者,其中胃癌21例,肝癌10例,淋巴瘤11例,乳腺癌24例,鼻咽癌6例,结直肠癌30例,肺癌18例。所有患者都是第一次做血细胞分析。将120例患者随机分为两组即治疗组和对照组,每组60例,其中治疗组采取促红细胞生成素(EPO)重组方法来治疗贫血并发症,而对照组只是采取常规性补铁治疗,对两组的治疗效果以及血红蛋白和红细胞的含量进行对比。结果:从疗效来看,两组的显效率分别为56.67%和0,治愈率分别为93.34%和13.30%,组间比较,差异具有统计学意义(P<0.05)。从两组的血红蛋白以及红细胞来看,各种比较指标均表明治疗组的治疗效果要明显优于对照组,差异具有统计学意义(P<0.05)。结论:促红细胞生成素治疗肿瘤并发性贫血具有较好的效果,能够有效提高患者的生活质量。
Objective: To discuss the clinical treatment of anemia complicated with cancer. Methods: From January 2009 to January 2014 and county People’s Hospital of chemotherapy patients selected 120 cases of patients with leukemia, excluding patients with gastric cancer in 21 cases, 10 cases of liver cancer, 11 cases of lymphoma, 24 cases of breast cancer , 6 cases of nasopharyngeal carcinoma, 30 cases of colorectal cancer, 18 cases of lung cancer. All patients are doing their first blood cell analysis. One hundred and twenty patients were randomly divided into two groups: treatment group and control group, with 60 patients in each group. Among them, the treatment group took the erythropoietin (EPO) recombination method to treat the anemia complication, but the control group only took the conventional iron therapy , The two groups of treatment and hemoglobin and erythrocyte content were compared. Results: In terms of curative effect, the effective rates of the two groups were 56.67% and 0 respectively, and the cure rates were 93.34% and 13.30% respectively. There was significant difference between the two groups (P <0.05). From the two groups of hemoglobin and red blood cells point of view, a variety of indicators show that the treatment group was significantly better than the control group, the difference was statistically significant (P <0.05). Conclusion: Erythropoietin has a good effect in treating patients with anemia of tumor and can effectively improve the quality of life of patients.